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Adenomyoepithelioma of the breast: a proposal for classification
Breast lesions with a prominent myoepithelial cell
component constitute a heterogeneous group of
benign and malignant neoplastic proliferations. These
lesions are often dual epithelial–myoepithelial, but
may be purely myoepithelial cell in nature. Benign
epithelial–myoepithelial lesions typically maintain the
morphology and immunophenotype of the normal
bilayer epithelial myoepithelial structures. However,
the distinction between the two cell components is
not always clear-cut in malignant lesions in which
the histogenesis of myoepithelial cells remains uncer-
tain. Neoplastic biphasic epithelial–myoepithelial
lesions of the breast include adenomyoepithelioma
(AME), pleomorphic adenoma and adenoid cystic car-
cinoma. Four histological patterns of classical AME
have been described: tubular, lobulated, spindle-cell
and adenosis variants. Overlapping patterns occur
and some AMEs display an intraductal papillary pat-
tern that may represent a fifth variant. AME can be
benign or malignant. Classical AME may show atypi-
cal features, which are not sufficient for the diagnosis
of malignancy (atypical AME). Atypical AME is recog-
nised as a lesion of uncertain malignant potential
with limited metastatic capability. Based on the histo-
logical features, we propose a classification of malig-
nant AME (M-AME) into three variants: M-AME
in situ, M-AME invasive and AME with invasive carci-
noma. In this review, we provide an overview of
myoepithelial lesions of the breast focusing on the
classification of AME to improve not only the consis-
tency of reporting but also help to guide further man-
agement decision-making.
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Introduction
The human breast incorporates a branching ductal
network lined by an inner layer of polarised luminal
epithelial cells and an outer layer of myoepithelial
cells (MECs), separated from the stroma by a laminin-
rich basement membrane. End-differentiated MECs,
like epithelial cells, derive from precursor stem cells
positioned within the luminal epithelial compart-
ment.1,2 MECs, localised at the epithelial stroma inter-
face, communicate with both compartments and may
function as a guardian of tissue integrity by main-
taining tissue polarity.1-3 End-differentiated MECs are
distinguished from luminal epithelial cells and myofi-
broblasts by location, shape and immunoprofile
(Table 1). Myoepithelial and basal cell differentiation,
detected by cytokeratin (CK)14, CK5/6, CK17, vimen-
tin and epidermal growth factor receptor (EGFR)
immunohistochemistry, is also seen in 20–35% of
invasive breast cancers (IBCs) with a smaller propor-
tion expressing myoepithelial myoid markers; e.g.
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smooth muscle actin (SMA) and smooth muscle myo-
sin heavy chain (SMMHC).3,4 Global expression stud-
ies have confirmed the existence of a subset of IBC
that features a basal/myoepithelial profile and com-
prises 15–20% of all breast tumours.3 It is important
to differentiate IBCs that express myoepithelial or
basal markers and frequently associated with a poor
prognosis from breast lesions with a dual epithelial
myoepithelial phenotype, which may display a
benign, locally aggressive or malignant clinical
course.
Breast lesions with a myoepithelial cell
component
Breast lesions with prominent MEC components con-
stitute a heterogeneous group of lesions, which are
often dual epithelial–myoepithelial but may be purely
MEC in nature (Table 2). Neoplastic epithelial–myoep-
ithelial lesions of the breast include AME [classical
(benign and atypical) and malignant], pleomorphic
adenoma and adenoid cystic carcinoma.4,5 Benign
epithelial–myoepithelial lesions typically maintain the
morphology and immunophenotype of the normal
bilayered epithelial myoepithelial structures and are
considered neoplastic proliferations of separate epithe-
lial and myoepithelial cells. However, in malignant
lesions the distinction between the two cell compo-
nents is not always clear-cut, and the histogenesis of
myoepithelial cells in these lesions remains uncer-
tain.6-9 In practice, we consider the presence of a
coexistent benign-appearing biphasic component as
evidence of dual cell origin which progressed to a
malignant tumour with any aberrant phenotype due
Table 1. Myoepithelial cell markers commonly used in breast pathology
Marker Comments
1 Smooth muscle actin (SMA) SMA is a robust marker that is usually retained in poorly fixed or infarcted tissue. It is
typically strongly positive in myoepithelial cells (MEC). Assuming that internal controls are
appropriately positive, the absence of staining for smooth muscle actin is strong evidence
that there is no myoepithelial layer. The major weakness is lack of specificity. Staining of
myofibroblasts adjacent to carcinoma cells can make interpretation difficult
2 Smooth muscle myosin heavy chain
(SMMHC)
SMMHC is more specific than SMA and easier to interpret but it is a less robust marker due
to lower sensitivity and may not stain well in poorly fixed or infarcted tissue
3 P63 p63 is a homologue of the p53 tumour suppressor gene. p63 is more specific than SMA and
SMMHC with no staining of myofibroblasts and blood vessels. Like SMMHC, p63 is a less
robust marker than SMA. If the myoepithelial layer is attenuated, interpretation of p63 can
be difficult, as there are large gaps between positive nuclei. It is also a squamous cell
marker and can be expressed by lesional cells in some tumours
4 Basal cytokeratins (CK 14, CK5, CK5/6
and CK17)
They are expressed in MECs but are also expressed in some normal and hyperplastic
epithelial cells. Basal CKs frequently stain MECs weakly, so they should not be used as
myoepithelial markers on their own, but they can be very helpful if they are positive
5 CD10 (the common acute
lymphoblastic leukaemia antigen)
CD10 is similar to SMMHC staining in the majority of cases but in our experience, it is less
robust with expression absent in some cases for unknown reasons. Therefore, it can be
useful when it is retained and positive. Focal background staining of stromal myofibroblasts
can be seen with both CD10 and SMMHC, but CD10 shows a higher rate of non-specific
staining of epithelial cells and it does not stain blood vessels
6 Calponin Calponin, similar to SMMHC, is a marker of terminal smooth muscle differentiation, and it is
more specific for MECs than SMA. Calponin, like caldesmon, is an actin-binding protein
found in appreciable quantity in a variety of smooth muscles and some non-muscle tissues.
Calponin has similar staining patterns to SMMHC
7 Other positive ME markers P40, podoplanin (D2-40), maspin, caveolin 1 and 2, nestin, 14-3-3 sigma (stratifin), S100, P-
cadherin
8 Negative markers HER2, EMA/MUC1, BerEP4, ER, PR, AR, GCDFP-15, EpCAM with negative or weak luminal
CKs and E-cadherin*
*In human mammary glands, the expression of low-molecular-weight luminal-type cyrokeratins (CK7, CK8, CK18, and CK19) and other
luminal enriched markers is characteristics of the end-differentiated luminal cells. HER2, human epidermal growth factor.
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to de-differentiation during carcinogenesis. Alterna-
tively, these tumours may arise from a single progeni-
tor cell (from which luminal breast carcinoma also
arises) with differentiation towards cells with both
luminal and basal/myoepithelial phenotypes. Molecu-
lar studies indicate that both components are neo-
plastic and clonally related with a common stem cell
origin.9-11 Regardless of histogenesis, diagnosis is
based on the recognition of the dual cell population,
using morphology and/or immunohistochemistry. In
our experience, MECs are easily identified in benign
AME; however, their identification in atypical and
malignant variants is more difficult, and discordance
between morphology and immunoprofile appears to
be correlated with the degree of malignancy.
Neoplasms composed entirely of MECs represent
one end of the spectrum of MEC proliferation. These
are exceptionally rare and limited to isolated reports
of benign myoepithelioma5 and myoepitheliosis,12 the
existence of which is not widely accepted, and malig-
nant myoepithelioma/myoepithelial carcinoma, now
regarded as a form of metaplastic carcinoma (MBC).4
The term ‘MEC carcinoma’ was used to describe rare
tumours composed of malignant spindle cells with
myoepithelial differentiation.13,14 Some of the
reported cases are CK8/18-positive,13-15 associated
with AME16 or in-situ or invasive carcinoma.17 There
is no internationally accepted definition of pure MEC
carcinoma. Most cases appear to represent either
MBC, malignant AME or AME with carcinoma.
Adenomyoepithelioma
H I S T O R I C A L O V E R V I E W
AME of the breast was first described by Hamperl in
1970,18 and further defined by several authors.12,19-
21 AME is defined as a biphasic neoplasm charac-
terised by small epithelium-lined spaces with inner
luminal ductal cells and a proliferation of variably
enlarged abluminal MECs.4 Although AME is gener-
ally regarded as a low-grade malignant tumour or a
tumour with low/uncertain malignant potential,22-25
current evidence suggests that AME comprises a spec-
trum of disease ranging from purely benign lesions to
frankly malignant tumours. However, given the rarity
of AME and the lack of a uniform classification sys-
tem to date, it has been difficult to comment upon
the biological significance of the different patterns of
this lesion with consequent challenges in clinical
management.
Tumours showing AME morphology with malig-
nant features have been variously described as ‘ma-
lignant AME’, ‘AME with malignancy’, ‘AME with




Terminal ducts lobular units and ducts (one layer at epithelial stroma interface). Typically express almost
all myoepithelial associated markers A subset of end differentiated MECs and neoplastic MECs may
lack expression of myoid markers and basal CKs1
Basal cells These are intermediate cells with a phenotype between end differentiated MECs and luminal epithelial
cells and show expression of low and high molecular weight CKs but lack expression of myoepithelial
specific markers, e.g. p63.1,2
These cells are frequently seen in the proliferative pool of usual ductal hyperplasia (UDH)
MEC hyperplasia In intraductal papilloma, in sclerosing adenosis and can be seen in fibroepithelial lesions. Myoid
metaplasia and hyperplasia can be seen in elderly people as isolated changes
Benign epithelial myoepithelial
lesions
Collagenous spherulosis, pleomorphic adenoma and benign AME. MEC may show mild alteration of
immunophenotype
Atypical MEC neoplasms Atypical AME
Malignant epithelial
myoepithelial lesions
Malignant AME (in-situ, invasive and AME with carcinoma). Adenoid cystic carcinoma,* MEC typically
show aberrant immunophenotype
Other lesions that show MEC
differentiation
Metaplastic carcinoma and basal-like breast carcinoma may show typical basal cells immunophenotype
with basal CK expression, less commonly myoid differentiation markers and rarely express p63 or p40
*Myoepithelial cells (MECs) of adenoid cystic carcinoma tend to be smaller, more hyperchromatic and basaloid appearing and have much
less cytoplasm than those of adenomyoepithelioma (AME). They are mixed with the epithelioid cells, line pseudolumina rather than forming
a bi-layer structure or sheets and clusters of cells.
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carcinoma’ and ‘epithelial–myoepithelial carcinoma’.4
Classification of these lesions is often subjective, given
the spectrum of morphology and immunoprofile,
intratumoural heterogeneity and difficulty in distin-
guishing between the epithelial and MEC components
in malignant tumours. Using a three-tiered approach,
AME has been classified by some authors as benign,
infiltrating and malignant.12,26-28 Later, the term
‘atypical AME’ was proposed as an alternative to infil-
trating AME, with stromal infiltration not a diagnos-
tic prerequisite12,29,30 These atypical AMEs display
clinical behaviour intermediate between benign and
malignant AME30,31 and show an intermediate
immunoprofile, termed ‘borderline AME’ by some
authors.6 However, precise categorisation of AME
remains challenging. In a central recent large collab-
orative study, a histological review of 43 cases unani-
mously considered to represent bona fide classical
AME, 18 (42%) cases were reclassified as atypi-
cal/malignant AME.9
The 5th edition of the World Health Organisation
(WHO) classification of breast tumours4 categorises
breast AME into AME and malignant AME,4 acknowl-
edging that AME encompasses benign and atypical
forms. For consistency of reporting, we prefer the
classification of benign, atypical and malignant AME
with the term ‘malignant AME’ (M-AME) used to
encompass malignant in-situ or invasive tumours,
regardless of the malignant cell type.
In this review, we discuss the genetics of AME,
the classification of classical AME into benign and
atypical variants and the categorisation of malig-
nant AME with emphasis on management implica-
tions.
G E N E T I C A L T E R A T I O N S
Benign epithelial–myoepithelial lesions are considered
to develop from separate epithelial and myoepithelial
progenitor cells and often maintain the morphology
and immunophenotype of the normal bilayered
epithelial myoepithelial structures. The histogenesis of
myoepithelial cells in malignant lesions remains
uncertain, and the distinction between the two cell
components is not always clear-cut. In a previous
study, forced expression of Harvey rat sarcoma viral
oncogene homologue (HRAS) (Q61R) in non-
malignant oestrogen receptor (ER)-negative breast
epithelial cells with or without a PIK3CA somatic
knock-in resulted in the development of a lesion
showing the cardinal features of AME, including the
expression of MEC markers, a reduction in E-cadherin
expression and an increase in AKT signalling.9
Regarding human tumours, AME appears to repre-
sent an example of genotypical–phenotypical correla-
tion in the breast with variation in the genomic
landscape according to ER status.9 While ER-positive
AME frequently harbours mutations affecting PIK3CA
or AKT1, up to 60% of ER-negative AMEs are under-
pinned by mutations affecting the HRAS Q61 hot-
spot, which frequently coexist with PIK3CA or
PIK3R1 mutations.9,32 HRAS Q61 hot-spot mutations
coexisting with PIK3CA mutations have been
reported in up to 50% of epithelial–myoepithelial car-
cinomas of the salivary gland, suggesting an associa-
tion between this constellation of genetic alterations
and epithelial–myoepithelial differentiation regardless
of anatomical location.33 In a next-generation
sequencing (NGS) study of 19 AMEs,34 HRAS and
PIK3CA hot-spot mutations were identified in six
(32%) and 11 (58%), respectively, and all but one
were clonal. In-vitro forced HRAS expression (Q61R)
in normal epithelial cell lines resulted in a highly dis-
organised growth pattern, partial loss of epithelial
phenotype and acquisition of aberrant myoepithelial
differentiation.
It is recognised that AMEs may produce myxochon-
droid matrix, akin to pleomorphic adenomas.35 A
study investigating the presence of HMGA2 and
PLAG1 rearrangements, characteristic of pleomorphic
adenoma,36 revealed the presence of an HMGA2–
WIF1 fusion,10 suggesting that a subset of AME
might be genetically related to pleomorphic adeno-
mas. Although some authors have not identified
pathognomonic non-synonymous mutations in malig-
nant AME compared to their benign counterparts,32
other investigators have reported changes associated
with malignancy in AME, including hot-spot muta-
tions of the TERT gene,9 homozygous deletion of
CDKN2A (p16INK4a)9 and amplification of the MYC
gene.37
Classical (benign and atypical) AME
C L I N I C A L F E A T U R E S
Classical AME is rare, accounting for fewer than
0.5% of breast tumours.4 It predominantly affects
older women, with rare cases reported in men.27 In
our experience of 55 AMEs in Nottingham, the mean
age of patients with benign and atypical AME was
54 years (range = 15–76) and 60 years
(range = 40–93), respectively. AME usually presents
as a solitary palpable mass, occasionally associated
with serous nipple discharge. Most are located cen-
trally in the breast. Breast cancer screening
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programmes have led to the discovery of smaller
AME lesions. Radiologically, AME forms a round or
lobulated dense mass with margins that may be indis-
tinct. Calcification is sometimes seen on mammogra-
phy. Local recurrences have been reported in
approximately 10%.12,19 On rare occasions AME may
be associated with genetic syndromes, e.g. neurofibro-
matosis type 1.4
M A C R O S C O P I C F E A T U R E S
Classical AME is usually nodular, with a generally
defined margin. Focal cystic degeneration and calcifi-
cation may be seen. In our experience, the mean size
of benign AME was 11 mm (range = 2–40 mm) and
atypical AME was 20 mm (range = 6–35 mm).
M I C R O S C O P I C F E A T U R E S
Classical benign AME comprises epithelial and MECs
with varying ratios within and between tumours.
MECs usually dominate and are more numerous than
the single basal layer component of the epithelial
myoepithelial bilayer of normal breast lobules, adenosis
nodules or simple papillomas (Figure 1A–D). They can
be spindle-shaped or epithelioid with clear or eosino-
philic cytoplasm. In classical benign AME, the MECs
are often small and uniform without cytological atypia
or increased mitotic activity. MECs may merge to form
large sheets within which the second population of
epithelial cells is present. Epithelial cells are polygonal
or columnar with abundant cytoplasm and form glan-




Figure 1. Low-power view of classical adenomyoepithelioma showing peripheral thick fibrous layer and appearances that overlap with pleo-
morphic adenoma, duct adenoma or a sclerosed papilloma with florid hyperplasia and squamous metaplasia (A). B, two cell types with
epithelial cells showing eosinophilic cytoplasm and prominent myoepithelial cells showing pale cytoplasm. Focal squamous differentiation is
seen in the upper part of the image. High-power view highlighting the two cell types and the lack of atypia, necrosis or high mitotic figures
(C). E-cadherin staining highlighting the differential staining in the epithelial (strong staining) and myoepithelial (weak staining) cells of ade-
nomyoepithelioma (AME) (D). E, AME with foamy cell changes.
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foamy and sebaceous metaplasia may be seen (Fig-
ure 1B,E). AMEs rarely contain foci mimicking collage-
nous spherulosis or display a focal chondromyxoid
appearance. Sclerosis and intervening fibrosis are fre-
quently present, giving the lesion its characteristic
architecture. Satellite nodules may occur around the
main tumour. Peripheral fibrosis may be observed, but
most AMEs do not have a capsule.
Four histological patterns of AME have been
described: tubular, lobulated, spindle cell and adenosis
variants.4,12 We and others25,27 have seen cases with
a prominent intraductal papillary pattern,4,12,26
which represents a fifth (papillary) variant. Some
lesions display overlapping patterns and do not
always conform to a specific morphological variant.
Tubular AME comprises a proliferation of tubular
structures surrounded by MECs with clear, glycogen-
rich cytoplasm. This resembles tubular adenoma, but
the MECs are larger with a greater degree of prolifera-
tion. The tubular structures are arranged as
terminal-type ducts, sometimes with a lobular archi-
tecture, often compressed into cords. Tubular AME is
usually circumscribed but unencapsulated with an
expansile edge (Figure 2A), in contrast to the tubular
proliferations encountered in nodular adenosis or
florid sclerosing adenosis. Focal microscopic extension
into adjacent normal breast tissue may be seen.27
In spindle cell AME, the MEC component predomi-
nates with florid proliferation and, as the name
implies, spindle cell morphology (Figures 2B,C).
Epithelial lined tubules can be difficult to identify.
Nuclei may show a palisaded arrangement simulating
a schwannoma. Sometimes the MECs have a plasma-
cytoid appearance, with eccentric nuclei and eosino-
philic glassy cytoplasm resembling the ‘hyaline’ cells
of pleomorphic adenoma. The cells may also have
abundant eosinophilic cytoplasm imparting a ‘myoid’
appearance, simulating a leiomyoma. The distinction
rests upon identification of epithelial-lined luminal
spaces, assisted by immunocytochemistry. The mar-
gin tends to be pushing/circumscribed.
Lobulated AME comprises nests of cells, predomi-
nantly myoepithelial, which generally have eosino-
philic cytoplasm and tend to be plumper than those
seen in other AME variants. The cells are arranged in
clusters, surrounded by dense ‘hyaline’ sclerotic col-
lagenous matrix material that probably reflects pro-




Figure 2. Classical adenomyoepithelioma with tubular growth pattern (A). B,C, The spindle-cell pattern with elongated spindle-shaped
myoepithelial cells (MECs). D, Classical adenomyoepithelioma (AME) with papillary growth pattern. The diffuse prominence of the myoep-
ithelial cell component and the pattern of myoepithelial cell proliferation together with the immunoprofile help to differentiate these lesions
from intraductal papilloma with focal MEC proliferation (see Figure 3B). No atypia or increased mitotic activity are seen to qualify the lesion
into atypical AME. E, Another case of papillary AME with unusual papillary growth pattern features papillary cores covered by MECs. F,
AME with myoepithelial adenosis-like pattern and CK14 IHC (G).
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material. The margin is usually ill-defined and irregu-
lar.
AME may have a prominent papillary component
and is distinguished from intraductal papilloma by
the significant increase in the MEC component
throughout the lesion (Figure 2D,E). This variant
may overlap morphologically with papilloma with
myoepithelial cell hyperplasia (see Differential diagno-
sis).
An exceptionally rare variant of AME is charac-
terised by a diffuse infiltrative pattern resembling
microglandular adenosis (MGA),38,39 variously
described as adenomyoepithelial adenosis,20 adeno-
myoepithelioma with apocrine adenosis, AME with
adenosis structure40 and tubular AME.39 We prefer
the designation of ‘AME with adenomyoepithelial
adenosis pattern’ to avoid confusion with apocrine
adenosis and tubular AME. Although these lesions
closely resemble MGA at low magnification, MGA is
monophasic and lacks a myoepithelial component,
whereas this lesion has a biphasic character.39 This
AME variant typically displays an infiltrative appear-
ance with a nested rather than a single-cell pattern,
and is not associated with a desmoplastic reaction
(Figure 2F,G).
A T Y P I C A L A M E
Atypical AME has been defined as AME that possesses
some, but not all, the features of malignancy: over-
growth of the epithelial or myoepithelial component,
mild to moderate cytological atypia, and increased
mitotic activity [> 3 per 10 high-power fields (HPF)]
with or without mildly infiltrative growth pattern,
and/or focal necrosis.30,31 Using these criteria,
approximately 50 and 25% of cases are classified as
classical and atypical AME, respectively.30,31 Other
authors have also considered prominent cytological
atypia, prominent eosinophilic nucleoli and mitotic
count up to five per 10 HPF as features of atypical
AME.29
It is our experience that prominent cytological aty-
pia and occasional mitotic figures (more than
three and up to five mitoses per 10 HPF) can be seen
in all variants of AME and, in our view, these cases
should be classified as ‘atypical AME’ (Table 3 and
Figure 3A). We have seen two cases reported as
benign AME that developed limited nodal metastases,
and on review, mitotic figures and obvious cytological
atypia were observed in the MEC component.
Although the degree of atypia and/or the number of
mitotic figures that reliably distinguish AME from
atypical AME are not well-defined, we consider more
than three mitotic figures per 10 HPF and moderate
cytological atypia in the MEC component sufficient
for the diagnosis of atypical AME.5 In our experience,
a Ki67 index of > 10% in the MEC component also
favours atypical AME. Occasional mitotic figures (one
to two per 10 HPF) in an otherwise benign AME
should not trigger a diagnosis of atypical AME. At
the other end of the spectrum, AMEs showing multi-
ple atypical features (Table 3) should raise the suspi-
cion of malignant AME (see below), similar to the
approach used to classify a phyllodes tumour as
malignant rather than borderline.25
As cytological atypia increases, the distinction
between myoepithelial and epithelial cells becomes
less obvious and the immunoprofile gradually shows
aberrant expression that may not be concordant with
the morphology of the cell types. Infiltrative growth
pattern and tumour necrosis may be seen and corre-
late with an increasing risk of aggressive behaviour,
including local recurrences and the possibility of
metastatic disease.5,9,27
I M M U N O H I S T O C H E M I S T R Y
The immunohistochemical profile of AME highlights
the characteristic dual cell population. Although the
MECs are usually positive for MEC markers (Table 1)
the classical pattern of staining is not always
observed, with intra- and intertumoural variation.
Immunohistochemical findings should be evaluated in
conjunction with morphology, particularly as the
dominant cell type in AME may be of ‘intermediate
cell’ with MEC-type morphology but limited or aber-
rant expression of classical MEC immunohistochem-
istry markers. It is also noteworthy that p63, p40
and basal CKs (CK14 and CK5/6) may be expressed
in foci of squamous metaplasia. The glandular com-
ponent is composed of columnar or cuboidal cells that
are low molecular weight CK and epithelial mem-
brane antigen-positive. E-cadherin staining frequently
shows a biphasic pattern of staining with strong
membranous expression in the epithelial cells and
weaker, mainly cytoplasmic, expression in the MECs
(Figure 1D). A similar pattern of variably strong and
weak expression of low and high molecular weight
CKs may be seen in both epithelial and MECs. Benign
AME is typically positive for ER and PR, typically in
the epithelial cell component.
D I F F E R E N T I A L D I A G N O S I S
AME encompasses a broad range of differential diag-
noses with potential for diagnostic confusion and
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impact upon management recommendations.30 At
the benign end of the spectrum, distinction from
other benign breast lesions with epithelial and
myoepithelial elements can be challenging, as histo-
logical criteria are not well defined and diagnosis
often relies upon pathologists’ experience.35 In previ-
ous studies, 20% (four of 20),26 34% (12 of 35)35 to
50% (12 of 24)30 of cases, initially reported as AME,
were reassigned on histological review to different
categories. It is our practice to restrict the diagnosis
of AME to cases showing a classical biphasic epithe-
lial and myoepithelial growth pattern with MEC
prominence, proliferation and expansion. The distinc-
tion of AME with a papillary configuration from
papilloma with MEC hyperplasia may be difficult, and
is important due to the higher potential for local
recurrence associated with AME. MEC hyperplasia in
intraductal papilloma is typically focal (Figure 3B) in
contrast to AME, where it is generally diffuse.27 It is
also noteworthy that focal intraductal papilloma-like
areas may be seen in well-established AMEs, particu-
larly in the papillary variant, and should not change
the overall diagnosis of AME. IHC for MECs and
detection of HRAS mutations in AME may assist diag-
nosis.34,41
Pleomorphic adenoma shows prominent chon-
dromyxoid stroma and lacks the distinct biphasic phe-
notype, with an intermediate phenotype more
commonly (DD Figure 3C,D). The diffusely infiltrative
form of AME has a growth pattern similar to MGA
Table 3. Difference between the three categories of adenomyoepithelioma (AME)
Variable AME Atypical AME Malignant AME
Age Postmenopausal women
> 50 years
Postmenopausal women >50 years Postmenopausal women >50 years
Size Any size Any size, can be large May reach large size
Margins Circumscribed  lobulated or
slightly irregular/pushing
borders. May be encapsulated
Lobulated, circumscribed (or infiltrative as
in the AME with tubular and
adenomyoepithelial adenosis patterns)
Infiltrative (except M-AME in situ)
Intraductal
component
Often present in the whole or
part of the lesion
May be present Often lacking
Cytological
atypia
No Mild to moderate Marked
Necrosis No None or focal May be present
Mitotic counts in
the MECs
< 3/10 HPF 3–10/10 HPF >10/10 HPF (may show atypical forms)
IHC for MEC
markers
Nearly similar to normal May show aberrant phenotype Usually aberrant phenotype with
discordance between epithelial and




Absent Absent May be present
Local recurrences Yes (more than papillomas) More frequent More frequent (35%)49
Node metastasis No Very low (lesion of uncertain malignant




No Not reported Approximately 20%27,30
Local excision Complete excision to reduce
local recurrence risk
Complete excision with clear margin to
reduce local recurrence risk
Mastectomy or wide local excision with
radiotherapy based on the clinical and
imaging findings
IHC, immunohistochemistry; MEC, myoepithelial cell; HPF, high-power field.
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and is distinguished by its biphasic cellular composi-
tion. MGA shows diffuse strong S100 positivity but
lacks expression of other MEC markers, and is triple-
negative. To distinguish benign, atypical AME and M-
AME see Table 4.
P R O G N O S I S A N D T R E A T M E N T
Despite the rarity of AME and the lack of a uniform
approach to classification, current evidence suggests
that the majority of classical AMEs pursue a benign
clinical course and complete surgical excision is cura-
tive.4 Local recurrence may occur,27 more commonly
in the tubular variant.12 AME with the adenomyoep-
ithelial adenosis pattern is often extensive at diagno-
sis, and in our experience recurrence is more
common.
Recurrent AME may show atypical or malignant
features with higher potential for more aggressive
behaviour.38,42,43 The low recurrence rate observed
in recent years most probably relates to earlier diag-
nosis at smaller size and thorough evaluation of
resection margin status.27 Although distant metas-
tases from AMEs that apparently lacked significant
cytological atypia or increased mitotic activity have
been reported42,44 and cited in other studies,9 we
believe that classical benign AME is an indolent
tumour that may recur locally if incompletely excised,
with metastatic potential restricted to atypical and
malignant AMEs. Reported metastatic events in so-
called benign AME may reflect undiagnosed atypia
and mitotic activity in the MEC component at initial
diagnosis. The use of the term ‘benign metastasising
AME’ to describe AME lesions in the lung42,44 is con-
fusing. Consideration of these cases suggests that at
least some may represent additional primary lesions,
as both benign20,37-39 and malignant45-47 AME vari-
ants have been described in the lung.
A B
C D
Figure 3. A, Atypical adenomyoepithelioma with increased mitotic figures (highest mitotic activity was captured in the field) but no signifi-
cant atypia or other features of malignancy, therefore it is classified as atypical adenomyoepithelioma (AME). B, Focus of myoepithelial cell
(MEC) proliferation in otherwise typical intraductal papilloma. Differential diagnosis figures (DD). C,D, Pleomorphic adenoma with papillary
growth pattern, chondromyxoid areas and calcification. Cytology shows cells with intermediate features between epithelial and myoepithelial
cells rather than the distinct biphasic appearances of AME.
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Malignant adenomyoepithelioma
The rarity of these tumours, with their spectrum of
morphological changes, makes diagnosis and classifi-
cation in clinical practice challenging and subjective.
Importantly, current terminology does not translate
into specific management regimes and malignant
tumours with AME components are treated in the
same way, despite showing considerable morphologi-
cal variation. We propose a pragmatic approach to
the categorisation of these lesions to help guide fur-
ther individualised management decisions, based on
our own experience in the context of the current lit-
erature. This (i) focuses upon the distinction of
tumours that are considered equivalent to DCIS (ma-
lignant in-situ tumours) from those that are equiva-
lent to invasive malignancy and (ii) presents a system
for the classification of malignant AME tumours
equivalent to that of the papillary carcinoma,30,48 as
each may lack a peripheral MEC layer at the
epithelial–stroma interface. We suggest that the term
‘malignant adenomyoepithelioma’ (M-AME) be used
to include three variants: M-AME in situ, M-AME
invasive (also referred to as ‘invasive adenomyoep-
ithelial carcinoma’ or ‘IBC, adenomyoepithelial pat-
tern’) and AME with invasive carcinoma (see below,
Figures 4 and 5).
C L I N I C A L F E A T U R E S
M-AME of the breast is rare, and usually affects older
women.49 In our unpublished series of 55 AMEs the
mean age at presentation was 65 years (range = 40–
93). Some patients present with a longstanding mass
with recent rapid size increase. The size is usually lar-
ger than benign AME.50 In our series, the mean size
of M-AME was 29 mm (range = 16–50 mm). In
patients with nodal or distant metastases, size tends
to be larger than those without metastases
(range = 10–170 mm, median = 40 mm).49
Table 4. Difference between the three categories of malignant adenomyoepithelioma (M-AME)*
Variable M-AME in situ M-AME invasive AME with invasive carcinoma





or MECs but with defined
margins (intraductal)
Epithelial, myoepithelial or both; invasive component often





Variable Significant Variable based on the grade













staging pTis Based on the invasive component if distinct from the in-situ
component otherwise based on the whole lesion.
Based on the invasive
component only
Grade Nuclear grade Nottingham grade Nottingham grade





No (hormone therapy can
be offered if ER+ and
large size)
Hormone therapy if ER-. Discussion for chemotherapy As for invasive carcinoma
*Cases with overlapping features exist and a pragmatic approach should be considered with interpretation of all findings. Degree of uncer-
tainty should be highlighted in the report. MEC, myoepithelial cells; DCIS, ductal carcinoma in situ; ER, oestrogen.
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M A C R O S C O P I C A P P E A R A N C E
M-AME shows varied macroscopic appearances from
a multilobulated, well-defined mass, similar to classic
AME, to a poorly defined mass with infiltrative bor-
ders. M-AME is usually firm in consistency, some-
times with cystic change. Necrosis is seen in more
than half of all cases.49
M I C R O S C O P I C F E A T U R E S
M-AME in situ
M-AME in situ includes lesions with a classical AME
architecture in which the epithelial component shows
features of DCIS (Figure 4). The atypical cells show a
cribriform or solid growth pattern with a well-defined
margin or evidence of development within an
intraductal-like structure. A peripheral MEC layer at
the epithelial stroma interface is typically seen in the
intraductal component and in small satellite foci in
immediately adjacent tissue. In the main lesion, this
layer is often focal or difficult to identify in view of
the presence of lesional MEC marker-positive cells
within the tumour (Figure 4). These tumours should
be managed as in-situ lesions (DCIS; pTis). Akin to
encapsulated and solid papillary carcinomas,3,51 M-
AMEs with the configuration of DCIS but lacking
peripheral MECs at the epithelial stroma interface
should be low or intermediate-grade to be categorised
as in situ. The presence of high-grade cytological fea-
tures without evidence of an intraductal growth pat-
tern or a peripheral MEC layer may be best regarded
as M-AME invasive for management purposes.
Rarely, the AME shows expansion of the MEC com-
ponent with atypical features sufficient for a diagnosis
of malignancy (Table 3) but with pushing margins,
an intraductal growth pattern or a peripheral MEC
layer and no features of invasion. These are consid-
ered part of the spectrum of the M-AME in situ.
M-AME invasive (synonym: invasive
adenomyoepithelial carcinoma)
This is a tumour that displays a dominant AME
architecture but also has features sufficient for a diag-
nosis of malignancy including cytological atypia,
increased mitotic activity and necrosis associated with
frankly invasive foci and an accompanying stromal
response (Figure 5A). The malignancy in these
tumours can affect the luminal epithelial or myoep-
ithelial components or both (Figure 5B). The transi-
tion from atypical to malignant and from in situ to
invasive foci tends to be gradual, with merging of the




Figure 4. Malignant adenomyoepithelioma in situ showing appear-
ances and immunoprofile in keeping with DCIS (A). B, E-cadherin
staining, which highlights the differential staining in the epithelial
(strong staining) and myoepithelial (weak staining) cells. Smooth
muscle myosin heavy chain stain (C) in one area of the tumour
shows focal preservation of peripheral myoepithelial cells at the
epithelial stroma interface with no evidence of transition from in-situ
to invasive lesion within the ducts that show differential preservation
of myoepithelial cells providing evidence of an intraductal growth
pattern in a case of malignant adenomyoepithelioma in situ.
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called ‘malignant myoepithelioma/epithelial–myoep-
ithelial carcinoma’.25 These tumours may also be
referred to as ‘invasive adenomyoepithelial carci-
noma’ or ‘IBC, adenomyoepithelial pattern’ to convey
their designation as carcinomas for management pur-
poses regardless of the lineage/differentiation of the
malignant cell component.
The epithelial component may form solid nests,
ducts, cystic trabeculae, pseudopapillary or papillary
structures. Epithelial cells are recognised by the pres-
ence of abundant cytoplasm and their location lining
tubules/glandular structures. Epithelial cells are usu-
ally polygonal in shape but may be spindle-shaped
and form solid areas, making precise recognition diffi-
cult.49 Importantly, the malignant epithelial compo-
nent shows similar morphology and immunoprofile in
the well-developed AME areas and invasive compo-
nents (Figure 5C,D), in contrast to AME with invasive
carcinoma (see below). The MEC component is typi-
cally arranged around the epithelial cell component
in well-differentiated areas but in less differentiated
areas it may disappear, be present as a small compo-
nent or may form solid strands, trabeculae or large
sheets of cells with malignant features. It may be the
predominant component and lose its relationship with
the epithelial component.
Although these tumours are classified as invasive,
they are likely to behave in a more indolent fashion
than AME with invasive carcinoma (see below) due
to the low volume of invasion relative to the overall
size of the lesion and the gradual transition that
occurs between in situ and invasive components. The
morphological arrangement of M-AME invasive is
reminiscent of invasive solid papillary carcinoma with
an expected similar clinical course and consideration
for a similar management plan. However, tumour
size, grade and receptor status should be assessed in
the invasive component which may alter prognosis
and necessitate additional diagnostic work-up, e.g.
clinical staging and sentinel lymph node biopsy.
AME with invasive carcinoma
This is a tumour that shows a dominant malignant
component that, if arising independently, would be
classified as IBC of conventional type, e.g. IBC-no spe-
cial type (NST), lobular or MBC.52,53 The distinguish-
ing feature is the coexistence of a classical AME. Each
component is distinct and the epithelium of the AME
component is morphologically different to that of the
neoplastic epithelial cells. As there is insufficient evi-
dence that the presence of a classical AME compo-
nent alters the clinical behaviour of these tumours,
we support the view that they should be managed as
per the index IBC.
These tumours are rare, and distinction between
AME with malignant transformation of the epithelial
component (M-AME) from invasive carcinoma with
co-existent benign AME54,55 is not always possible.
A B
C D
Figure 5. Malignant adenomyoepithelioma with invasion (A) showing malignant biphasic papillary growth pattern in some areas (B), with
other areas showing evidence of stromal invasion which is focal in one area (C) and extensive in other area (D) but these show the same
morphology and immunoprofile of the main tumour.
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AME associated with a distinct malignant spindle-cell
component, previously described as malignant
myoepithelioma/MEC carcinoma, is currently consid-
ered as AME with MBC.4 It is important to distinguish
this from entrapped proliferating spindle-shaped cells
in areas of fibrosis, e.g. following core biopsy, that
may mimic MBC. In this context, distinction of AME
with these changes from MBC involves a pragmatic
approach, including evaluation of the degree of cyto-
logical atypia in the spindle cell areas, location within
or adjacent to the AME, comparison with the various
components of the lesion, the presence of foci of carci-
noma including keratin immunopositivity, stromal
invasion outside the main lesion, the presence of lym-
phovascular invasion and lymph node metastases.
AME-like foci may also be observed in breast carci-
nomas that show morphological heterogeneity, e.g.
MBC. Breast carcinomas showing basal/myoepithelial
differentiation without a distinct AME component are
classified as IBC according to morphology regardless
of immunoprofile. A basal, but not myoepithelial,
phenotype appears to be an independent predictor of
outcome.56
I M M U N O H I S T O C H E M I S T R Y
M-AME may show an aberrant immunoprofile with
loss of distinction of the dual cell population.4 The
epithelial cell component may be positive for ER and
EMA/MUC1 and show strong E-cadherin membrane
expression. Complete absence of hormone receptor
expression has been reported in 40% of AMEs, associ-
ated with nuclear atypia, necrosis and/or increased
mitotic activity.9 HER2 is usually negative in these
tumours.
P R O G N O S I S A N D T R E A T M E N T
Metastases have been reported in 16–32% of tumours
classified as M-AME involving lung, brain, bone, thy-
roid, liver and axillary lymph nodes.9,21,27,49 Metas-
tases appear to be restricted to tumours larger than
2 cm,57 with histologically defined malignancy in the
myoepithelial or epithelial component.9 The time
from presentation to distant metastases ranges from
3 weeks to 12 years.49 The prognosis associated with
M-AME with distant metastases is poor.58,59
No adjuvant therapy has been proved to be effec-
tive in M-AME.49 Complete local excision is currently
recommended. M-AME with distinct carcinomatous
transformation and carcinoma arising in association
with classical AME should be managed in accordance
with standard breast cancer protocols.
Conclusion
AME comprises a spectrum of lesions with variable
morphology and clinical behaviour. Current evidence
supports further refinement of the classification of
AME to guide therapy. We suggest that classical AME
is classified into benign and atypical and M-AME into
M-AME in situ, M-AME invasive (invasive adenomy-
oepithelial carcinoma) and AME with invasive carci-
noma. Despite overlapping morphology and limited
data on the behaviour of the AME variants, this clas-
sification system is based on our increasing experi-
ence with these lesions, using conventional criteria
and a similar approach to that utilised for stratifying
papillary lesions, particularly solid papillary carci-
noma (in-situ and invasive).
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